RegeneRx(美國(guó))

RegeneRx

美國(guó)RegeneRx www.regenerx.comRegeneRx是一家公開(kāi)上市，臨床階段的生物制藥公司從事設(shè)計(jì)，研究和開(kāi)發(fā)有針對(duì)性的疾病，在滿(mǎn)足醫(yī)療需求的新型肽。RegeneRx的使命是研究和開(kāi)發(fā)新的藥品，保護(hù)和修復(fù)組織和器官的疾病，外傷或其他病理造成的損害。RegeneRxisapubliclytraded,clinical-stage,biopharmaceuticalcompanyen gagedinthedesign,researchanddevelopmentofnovelpeptidestargetedatdiseaseswithunmetmedicalneeds.RegeneRx’smissionistoresearchanddevelopnovelpharmaceuticalsthatprotectandrepairtissueandorgandamagecausedbydisease,traumaorotherpathology.RegeneRxacquiredtherightstoanovelpeptidefromtheNIHin1999.ThisintellectualpropertyforThymosinBeta4(Tβ4)allowedthecompanytodirectitsfocusontissueprotectionandrepairinmultiplediseaseindications.RegeneRx’smanagementteamisfocusedonmovingthreedistinctTβ4-baseddrugcandidatesthroughtheclinic:RGN-137,RGN-259andRGN-352.RegeneRxalsoholdsover60issuedpatentsorfiledpatentapplications